CCP
VIR icon

Corient Capital Partners’s Vir Biotechnology VIR Stock Holding History

Corient Capital Partners’s Portfolio VIR Stock Details VIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-15,449
Closed -$647K – 771
2021
Q4 		$647K Buy
+15,449
New +$605K 0.04% 319

Other funds holding VIR

SIAU
SB Investment Advisers (UK) London, United Kingdom $7.66B AUM 20.12% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return
APF
Alaska Permanent Fund Juneau, Alaska $1.51B AUM 22.23% 1-Year Est. Return

Corient Capital Partners's VIR Position: Q1 2022 in Review

Corient Capital Partners sold out of Vir Biotechnology (VIR) in Q1 2022, closing a stake of 15,449 shares — an estimated $647K sold.

Corient Capital Partners first reported a position in VIR in Q4 2021 and held it in 1 quarter. The position peaked at $647K in Q4 2021. 204 funds tracked by Wall St. Rank hold VIR as of Q1 2022.

  • Corient Capital Partners reported no remaining Vir Biotechnology position as of Q1 2022 after selling out during the quarter.
  • Corient Capital Partners sold 15,449 Vir Biotechnology shares in Q1 2022, an estimated $647K.
  • Corient Capital Partners first reported a position in Vir Biotechnology in Q4 2021 and held it in 1 quarter.
  • Corient Capital Partners's Vir Biotechnology position peaked at $647K in Q4 2021.
  • 204 funds tracked by Wall St. Rank held Vir Biotechnology as of Q1 2022.

Based on Corient Capital Partners's 13F filing for Q1 2022, filed 16 May 2022.